Neuropathy News and Research RSS Feed - Neuropathy News and Research

Novel technology could improve diagnosis of peripheral arterial disease

Novel technology could improve diagnosis of peripheral arterial disease

Approximately 8 to 12 million people in the United States alone are suffering from peripheral arterial disease (PAD), a common vascular problem that is caused by narrowing of the arteries as a result of plaque buildup. The plaque accumulation leads to an insufficient blood flow to the body's extremities and increases a person's risk for heart attack and stroke by up to six times. PAD is also one of the most serious complications of diabetes. [More]
Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Children with acute lymphoblastic leukemia who had a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study in the February 24 issue of JAMA. [More]
Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug. Investigators also found evidence of how it may be possible to protect young leukemia patients without jeopardizing cures. [More]
Researchers develop targeted approach that allows muscle to burn more energy

Researchers develop targeted approach that allows muscle to burn more energy

What started as an evolutionary protection against starvation has become a biological "bad joke" for people who need to lose weight. The human body doesn't distinguish between dieting and possible starvation, so when there is a decrease in calories consumed, human metabolism increases its energy efficiency and weight loss is resisted. [More]
Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

A drug used to treat patients with Crohn's disease and multiple sclerosis has helped scientists confirm how "viral reservoirs" form in patients living with HIV and also proven effective in animal trials at blocking the pathways to those reservoirs in the brain and gut, a team of researchers reported recently in the journal PLOS Pathogens. [More]
Advances in stem cell therapy can improve outcomes for patients with chronic diabetic foot ulcers

Advances in stem cell therapy can improve outcomes for patients with chronic diabetic foot ulcers

According to data presented at the 73rd Annual Scientific Conference of the American College of Foot and Ankle Surgeons, advances in stem cell therapy can significantly improve outcomes for patients with chronic diabetic foot ulcers. Use of stem cells to treat foot problems like diabetic ulcers may speed up the healing process, preventing infection and hospitalization during recovery. [More]
Research findings may point to new treatment for patients with Mitofusin 2 deficiency

Research findings may point to new treatment for patients with Mitofusin 2 deficiency

Researchers have discovered a novel role for Mitofusin 2, and the findings may point to a new treatment for patients with diseases caused by loss of the mitochondrial protein. [More]
Scientists identify first genetic marker linked to severe neurological toxicity

Scientists identify first genetic marker linked to severe neurological toxicity

Paclitaxel is a chemotherapeutic drug that has been shown to be highly effective when treating solid tumours, such as breast, ovarian and lung tumours. However, its use frequently causes peripheral neuropathies, neurological problems that affect the vast majority of patients. [More]
Study: Placental cells may possibly treat damaged nerves

Study: Placental cells may possibly treat damaged nerves

New findings suggest that placental cells may potentially treat damaged nerves possibly leading the way to new treatment for stroke patients. [More]
ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290. [More]
NYSCF, CMTA partner to advance research on genetic neuropathies

NYSCF, CMTA partner to advance research on genetic neuropathies

The New York Stem Cell Foundation Research Institute, a non-profit organization dedicated to accelerating cures through stem cell research, announced a collaboration today with the Charcot-Marie-Tooth Association, a patient-led disease foundation with the mission to advance research on genetic neuropathies that leads to the development of new therapies. [More]
Carboplatin and paclitaxel show promise for advanced thymic carcinoma

Carboplatin and paclitaxel show promise for advanced thymic carcinoma

A multicentre, phase II study of carboplatin and paclitaxel in chemotherapy-naïve patients with advanced thymic carcinoma has shown that the treatment has promising efficacy compared with standard anthracycline-based chemotherapy. [More]
New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes. [More]
MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). [More]
Researchers developing eye tests to evaluate diabetic neuropathy receive global recognition

Researchers developing eye tests to evaluate diabetic neuropathy receive global recognition

Researchers from QUT's Institute of Health and Biomedical Innovation developing eye tests to assess diabetic neuropathy and pave the way for earlier treatment are key partners in a consortium awarded $US1.1 million from the leading American medical research agency. [More]
PPMD, Santhera Pharmaceuticals collaborate to study Duchenne muscular dystrophy

PPMD, Santhera Pharmaceuticals collaborate to study Duchenne muscular dystrophy

Parent Project Muscular Dystrophy, the leading advocacy organization working to end Duchenne muscular dystrophy (Duchenne) and Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases, will collaborate on a benefit/risk study in Duchenne. [More]
Kidney disease patients can benefit from simple and structured exercise

Kidney disease patients can benefit from simple and structured exercise

Simple yet structured exercise can significantly improve kidney disease patients' quality of life as well as decrease their pain, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). [More]
Drug combination shows promise in patients with newly diagnosed multiple myeloma

Drug combination shows promise in patients with newly diagnosed multiple myeloma

The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology. [More]
Dr. Grace Campbell receives RNF Fellow Research Grant Award

Dr. Grace Campbell receives RNF Fellow Research Grant Award

The Rehabilitation Nursing Foundation (RNF) presents Dr. Grace Campbell, PhD BSN RN CRRN MSW, with the RNF Fellow Research Grant Award. RNF offers $30,000 in the form of multiple grants for research projects that address the clinical practice, educational or administrative dimensions of rehabilitation nursing. Dr. Campbell received her award at the ARN 40th Annual Educational Conference, October 29 - November 1, 2014 in Anaheim, CA. [More]